Fate-nk100

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

Fate-NK100 is an experimental therapy currently being studied in clinical trials for various advanced solid tumors, including colorectal cancer (CRC). It is being investigated as a potential treatment option, sometimes in combination with other drugs like cetuximab or trastuzumab. The trials are in early phases (Phase 1), meaning they are primarily focused on determining the safety and appropriate dosage of the drug. Fate-NK100 is not yet approved for treating CRC or any other cancer. The trials are looking at patients whose tumors may have specific characteristics, such as EGFR mutations or HER2 mutations, although the trial specifically for CRC (Regimen C) focuses on patients with advanced CRC or head and neck cancer, often in combination with cetuximab.

Mechanism of Action

Fate-NK100 is a type of immunotherapy. It involves natural killer (NK) cells, which are a type of immune cell that can recognize and kill cancer cells. Fate-NK100 is an engineered version of NK cells, designed to potentially enhance their ability to target and destroy cancer cells. The specific way it works and its exact molecular target are still being investigated in clinical trials.

Side Effects

Because Fate-NK100 is an experimental drug in early-phase trials (Phase 1) The full range of potential side effects is still being evaluated. Information from the NCT03319459 trial indicates that side effects are being closely monitored as part of the dose-escalation study to determine safety. Common side effects associated with NK cell therapies or related treatments can include flu-like symptoms Infusion reactions And potential effects on the immune system. More specific side effect data for Fate-NK100 in CRC patients is limited as it is still under investigation.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT03319459 Phase 1
Archived
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
United States

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
787 trials
Leucovorin
Other Medications
648 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.